Multi Drug Resistant Antibiotics Market: By Type of Bacteria (Multi Drug Resistant Enterococci, Multi-Drug Resistant Staphylococci, Gram Negatives, Others), By Disease (Drug-Resistant Tuberculosis, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others) and Geography

Purchase Option

$ 4400
$ 6600
$ 8900

Multi Drug Resistant Antibiotics Market size was valued at USD 9.20 billion in 2022 and is poised to grow at a CAGR of 7.2% from 2023-2029. The multidrug-resistant antibiotics market is driven by the increase in the prevalence of drug-resistant bacterial infections such as multi-drug-resistant TB. In addition, an increase in R&D activities to develop the new generation of multi-drug resistant antibiotics by the marketers coupled with the government and non-government organizations' initiatives and funding are expected to boost the market growth over the forecast period. Furthermore, recent drug resistance antibiotic approvals and promising pipeline drugs are expected to bolster the antibiotic resistance market over the forecast period.

However, high cost of R&D and lack of effective antibiotics are expected to hamper the market multi-drug resistance antibiotics market during the forecast period. Since the discovery of penicillin in 1928, a large number of antibiotics have been used for human therapy, as well as for farm animals and even for fish in aquaculture, resulting in the selection of pathogenic bacteria resistant to multiple drugs. This multidrug resistance may be generated by two mechanisms. One is bacteria may accumulate multiple genes, each coding for resistance to the single drug, within a single cell. Another mechanism is increased gene expressions that code for multidrug efflux pumps, which affect a wide range of drugs. Multi-drug resistant bacteria are formed due to the excessive use of antibiotics in various applications such as prophylactic use for surgery, or immunocompromised patients and other applications. Multi-drug resistant antibiotics are the new generation antibiotics that fight against the drug-resistant bacteria. In August 2017, U.S. FDA approved The Medicines Company abomere (meropenem and vaborbactam) for adult patients with urinary tract infections, including pyelonephritis. Vabomere also inhibits certain types of resistance mechanisms used by bacteria. In May 2014, U.S. FDA approved Durata Therapeutic  (acquired by Actavis) Dalvance (dalbavancin), a new anti-bacterial drug for the methicillin-resistant Staphylococcus aureus (MRSA) infections.

Multi Drug Resistant Antibiotics Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

7.2%

Largest Market

North America

Fastest Growing Market

Asia Pacific
Multi Drug Resistant Antibiotics Market Dynamics

Emergence of antimicrobial resistance is a major concern, particularly in low and middle-income countries. Multi drug resistance antibiotics market is at growing stage owing to the availability of limited drug resistant antibiotics and there is a huge development need for the novel drugs. The market has many players who are actively participating in the development of the new treatment for multi drug resistant bacterial diseases. For instance, in February 2017, Discuva Ltd., drug discovery company expanded its collaboration with F. Hoffmann-La Roche AG in development of new antibiotic for the life-threatening infections caused by multi drug resistant bacteria and collaboration was originally initiated in February 2014. Furthermore, government and non-government organizations are funding in R&D and spreading awareness related to multi drug resistant antibiotics. Development of novel antibiotics such as plazomicin (in Phase III CL) by Achaogen, Cadazolid (in Phase III CL) by Acetlion Pharmaceuticals and many other companies and their expected commercialization in coming years may drive the market growth furthermore.

Multi Drug Resistant Antibiotics Market Segmentation

By Type of bacteria
  • Multi Drug Resistant Enterococci
  • Multi Drug Resistant Staphylococci
  • Gram Negatives
  • Others
By Disease
  • Drug Resistant Tuberculosis
  • Others
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

Frequently Asked Questions

The multi drug resistant antibiotics market size was valued at USD 9.20 billion in 2023

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

The multi drug resistant antibiotics market key players are Achaogen Inc. Acetlion Pharmaceuticals Sanofi S.A Johnson & Johnson Services Pfizer Inc. Otsuka Pharmaceutical

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
1. Executive Summary
2. Global Multi Drug Resistant Antibiotics Market Introduction 
2.1.Global Multi Drug Resistant Antibiotics Market  - Taxonomy
2.2.Global Multi Drug Resistant Antibiotics Market  - Definitions
2.2.1.Type of Bacteria
2.2.2.Disease
2.2.3.Distribution Channel
2.2.4.Region
3. Global Multi Drug Resistant Antibiotics Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4. Global Multi Drug Resistant Antibiotics Market Analysis, 2019 - 2023 and Forecast 2024 - 2030
4.1.  Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5. Global Multi Drug Resistant Antibiotics Market  By Type of Bacteria, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
5.1. Multi Drug Resistant Enterococci
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Multi Drug Resistant Staphylococci
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Gram Negatives
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
5.4. Others
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.4.3. Market Opportunity Analysis 
6. Global Multi Drug Resistant Antibiotics Market  By Disease, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
6.1. Drug Resistant Tuberculosis
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Others
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
7. Global Multi Drug Resistant Antibiotics Market  By Distribution Channel, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
7.1. Hospital Pharmacies
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Retail Pharmacies
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Others
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
8. Global Multi Drug Resistant Antibiotics Market  By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
8.1. North America
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Europe
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Asia Pacific (APAC)
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
8.4. Middle East and Africa (MEA)
8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.4.3. Market Opportunity Analysis 
8.5. Latin America
8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.5.3. Market Opportunity Analysis 
9. North America Multi Drug Resistant Antibiotics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
9.1. Type of Bacteria Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1.Multi Drug Resistant Enterococci
9.1.2.Multi Drug Resistant Staphylococci
9.1.3.Gram Negatives
9.1.4.Others
9.2.  Disease Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1.Drug Resistant Tuberculosis
9.2.2.Others
9.3.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.3.1.Hospital Pharmacies
9.3.2.Retail Pharmacies
9.3.3.Others
9.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.4.1.United States of America (USA)
9.4.2.Canada
10. Europe Multi Drug Resistant Antibiotics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
10.1. Type of Bacteria Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Multi Drug Resistant Enterococci
10.1.2.Multi Drug Resistant Staphylococci
10.1.3.Gram Negatives
10.1.4.Others
10.2.  Disease Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Drug Resistant Tuberculosis
10.2.2.Others
10.3.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Hospital Pharmacies
10.3.2.Retail Pharmacies
10.3.3.Others
10.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Germany
10.4.2.France
10.4.3.Italy
10.4.4.United Kingdom (UK)
10.4.5.Spain
10.4.6.Rest of EU
10.4.7.
11. Asia Pacific (APAC) Multi Drug Resistant Antibiotics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
11.1. Type of Bacteria Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Multi Drug Resistant Enterococci
11.1.2.Multi Drug Resistant Staphylococci
11.1.3.Gram Negatives
11.1.4.Others
11.2.  Disease Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Drug Resistant Tuberculosis
11.2.2.Others
11.3.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Hospital Pharmacies
11.3.2.Retail Pharmacies
11.3.3.Others
11.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.China
11.4.2.India
11.4.3.Australia and New Zealand (ANZ)
11.4.4.Japan
11.4.5.Rest of APAC
12. Middle East and Africa (MEA) Multi Drug Resistant Antibiotics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
12.1. Type of Bacteria Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Multi Drug Resistant Enterococci
12.1.2.Multi Drug Resistant Staphylococci
12.1.3.Gram Negatives
12.1.4.Others
12.2.  Disease Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Drug Resistant Tuberculosis
12.2.2.Others
12.3.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Hospital Pharmacies
12.3.2.Retail Pharmacies
12.3.3.Others
12.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.GCC Countries
12.4.2.South Africa
12.4.3.Rest of MEA
13. Latin America Multi Drug Resistant Antibiotics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
13.1. Type of Bacteria Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Multi Drug Resistant Enterococci
13.1.2.Multi Drug Resistant Staphylococci
13.1.3.Gram Negatives
13.1.4.Others
13.2.  Disease Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Drug Resistant Tuberculosis
13.2.2.Others
13.3.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Hospital Pharmacies
13.3.2.Retail Pharmacies
13.3.3.Others
13.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Brazil
13.4.2.Mexico
13.4.3.Rest of LA
14. Competition Landscape
14.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
14.2.1.Achaogen Inc.
14.2.2.Acetlion Pharmaceuticals
14.2.3.Sanofi S.A
14.2.4.Johnson & Johnson Services
14.2.5.Pfizer Inc.
14.2.6.Otsuka Pharmaceutical
14.2.7.Eli Lilly and Company
15. Research Methodology 
16. Appendix and Abbreviations 
  • Achaogen Inc.
  • Acetlion Pharmaceuticals
  • Sanofi S.A
  • Johnson & Johnson Services
  • Pfizer Inc.
  • Otsuka Pharmaceutical
  • Eli Lilly and Company

Adjacent Markets